Green Resources Redux, Inc.
Tuesday, May 21, 2013

David H. Swenson, Ph.D.

Dr. Swenson was recently granted emeritus status from Saginaw Valley State University

Education 

  • B. S. (1970) in Biochemistry, University of Minnesota, Twin Cities Campus, magna cum laude.

  • Ph.D. (1975) in Experimental Oncology, University of Wisconsin, McArdle Lab. for Cancer Research, Madison, Wisconsin. Advisors: J. A. and E. C. Miller
  • Postdoctoral Research (1977) in Chemical Carcinogenesis, Institute for Cancer Research, Chester Beatty Research Institute, Chalfont St. Giles, Bucks., England. Advisor: P. D. Lawley.
 

Employment 

  • Research Chemist, National Center for Toxicological Research, Jefferson, AR, (1977‑1979).

  • Research Scientist, Genetic Tox. Unit (1979‑1982) and Senior Research Scientist (Biologist), Cancer and Viral Diseases Research Unit (1982‑1987), The Upjohn Co., Kalamazoo, MI.

  • Vice President and Senior Chemist, Karkinos Biochem, Inc., Phoenix, AZ (1987‑1991).

  • Associate Professor of Biochemical Toxicology, Dept. of Veterinary Physiology, Pharmacology and Toxicology, School of Veterinary Medicine (1990-1996).

  • Adjunct Associate Professor, Dept. of Biochemistry, Louisiana State University, Baton Rouge (January 1991‑June 1996).

  • H.H. Dow Chair of Chemistry, Dept. of Chemistry, Saginaw Valley State University, University Center, MI. (July 1996‑December 1998).  

 
 

Major Volunteer or Gratis Activities  

  • President, FloraPharm International Ltd., A Michigan Corporation. (1991-1996)
  • Member, Science Advisory Committee, Trisomy 21 Research, Inc
  • Member, Science Advisory Committee, State of Michigan Core Technology Alliance, for Biomedical Research Facilitation.
  • Member, Board of Directors for Good Neighbors Mission, a Saginaw foodbank
  • Member, Medical Review Team, Pardee Cancer Foundation, Midland, MI (1998-present)
  • Chair, Medical Review Team, Pardee Cancer Foundation, Midland, MI (2006-2008)
  • Member, Board of Trustees, Pardee Cancer Foundation, Midland, MI (2006-2008)
  • Grant review boards
  • Miscellaneous manuscript review               

Grant-Related Activities 

NCI Postdoctoral Fellowship No. 5F32‑CA05153, D.H. Swenson, for postdoctoral studies at the Chester Beatty Institute, Chalfont St. Giles, Bucks., ENGLAND; approx. $26,000 plus limited travel allowance. Funded 1975‑1977.  

Co‑Investigator, NCI Grant R01 CA30349, National Cancer Institute, awarded to L.H. Hurley, University of Texas, Austin, to study mechanism of action of CC‑1065. Dr. Swenson was employed by The Upjohn Company at the time. Precise title and amount of award not available. Funded 1981‑1984.  

Co‑principal Investigator, NCI Grant R01 CA30349‑4, National Cancer Institute, competitive renewal awarded to L.H. Hurley, University of Texas, Austin, to study mechanism of action of CC‑1065. Dr. Swenson was employed by The Upjohn Company at the time. Precise title and amount of award not available. Funded 1984‑1987.

Principal Investigator, National Cancer Institute Small Business Innovation Research Phase 1 Grant No. 1 R43 CA49354‑01 "Synthesis of Monomeric Carcinogen‑DNA Adducts" awarded to Karkinos Biochem, Inc., $50,000. Funded 1989‑1990. 

Principal Investigator, Dept. of Energy Small Business Innovation Research Phase 1 Grant No. DE‑FG03‑90ER81011 "Boronated Nitroimidazoles for Neutron Capture Therapy of Cancer" awarded to Karkinos Biochem, Inc., $50,000. Funded 1990.

Principal Investigator, National Cancer Institute Small Business Innovation Research Grant, "Boronated Nitroimidazoles for Neutron Capture Therapy." Declined because of new employment at LSU, $50,000; 1991. No possibility of conversion to University funds in this set‑aside program.

Principal Investigator, School of Veterinary Medicine Competitive Organized Research Program, "Effects of CC‑1065 and U‑71,184 on Oligonucleotide Duplexes." Funded for $4,000 for 1991‑1992.

Principal Investigator, Ethyl Corporation, "Metabolism of Diethyl Toluenediamine (DETDA)," C.R. Short and S.A. Barker, Co‑investigators. $110,000. Funded 1992‑1995.

Principal Scientist, gift from Chemsyn Science Laboratories to LSU Foundation, $3,000. Funded in 1991.

Co‑Investigator, LEQSF, "Veterinary Oncology Center," awarded to R. Beadle and B. Partington (Principal Investigators), Vet. Clin. Sciences. $44,475. Funded 1992.

Principal Investigator, School of Veterinary Medicine Competitive Organized Research Program, "Synthesis of a Prototype Chastigene." Funded for $4,476 for 1992‑1993.

Co‑Investigator, School of Veterinary Medicine Competitive Organized Research Program, "The Effects of Dietary Arginine Restriction on Urea Cycle Function and Nitrogen Excretion in Cats." $4,995 for 1992‑1993. Donna Dimski, Principal Investigator.

"Preliminary Studies on the Use of the Transgenic Mouse for Energy Related Risk Estimation of Mutation Induction." Center for Energy Studies, LSU, Pass‑Through Program. Funded for $20,000. William R. Lee, Principal Investigator.

Principal Investigator, The Upjohn Company, "Seed Money for Antisense Projects," $5,000, 1993.

Principal Investigator, Food and Drug Administration, "Preparation of 7‑Oxoethylguanine." $5,000, 1993.            

Co‑Investigator, School of Veterinary Medicine Competitive Organized Research Program, "Effect of Hyperbaric Oxygen on wound healing in normal and streptozotocin‑induced diabetic rats." G. Hosgood, P.I., $4,000, 1994.

Co‑Investigator, DOE/EPSCoR "Development of Mammalian and Nonmammalian Toxicological Indices to Investigate Risks Associated with Energy‑Related Waste." Principal Investigator, J.C. Means, Dept. Vet. Physiol. Pharmacol. Toxicol. $1,480,000. 1993‑1996.

Co‑Investigator, 95‑96‑ENH‑TR‑18, Louisiana Board of Regents Enhancement ALC/MS System for Adduct Analysis.   Principal Investigator, J.C. Means, Dept. Vet. Physiol. Pharmacol. Toxicol. ca. $368,000. 1996.

Co‑Principal Investigator, Michigan DEQ Electrowinning of Metals from Plating Waste.  $64,000, 1996‑1997.

Principal Investigator, Pharmacia and Upjohn Company. A Search for New Antibacterial Therapeutic Targets.  Research Agreement, $23,400, 1997‑1998. 

Principal Investigator, FRIENDS of TRI, "Inhibitors of CBS for Down Syndrome Research" Grant, $120,000, 1997‑1998.

Principal Investigator, Allen Foundation, Midland, MI, “Gene-nutrient Interactions in the Etiology of Alzheimer’s Disease: Intervention Strategies to Reduce Risk.” Grant, $119,311, 1999-2002.

Principal Investigator, Pharmacia and Upjohn Company. Building a Genome.   Research Agreement, $28,000, 1999.

Principal Investigator, Zdanowicz Family Foundation.  “Mutational Analysis of Folate/SAM Pathway Genes in Down Syndrome Cells Using a Standardized Cell Culture-based Population.”  Grant, $20,681, 1999-2000.

D. S. Karpovich (P.I), G. M. Lange, D. Swenson, R. Trdan, "Understanding the Fate of DDT in the Water, Sediment, and Biological Systems in the Pine River: Establishing a Long Term Picture of the River's Health", Funded by the Saginaw Bay Watershed Initiative Network.  Amount: $22,859.  Project duration: July 1999 thru December 2000.

Principal Investigator, Zdanowicz Family Foundation.  “Metabonomics in Down Syndrome.”  Grant, $24,000, 2001-2003.

George Puia, P.I., and D.H. Swenson.  Saginaw Bay Watershed Initiative Network.  “Sustainable Aquaculture Initiative.”  Grant, $28,713.  2001.

Principal Investigator, The Allen Foundation.  “Endowment for Nutrition-Related Health Research.” $1,000,000.  2000 - 2003.

D. S. Karpovich (P.I.) and D. H. Swenson, “Acquisition of Equipment for Earth Science Projects”. An MRI grant awarded by the National Science Foundation.  Amount: $196,020;  project duration: September 2001 thru September 2004.

D. S. Karpovich, C. H. Schilling, and D. H. Swenson, “Smart processing of biodiesel and fuel ethanol on Michigan farms,” Michigan Biomass Energy Program, Energy Office, Michigan Department of Labor and Economic Growth.  $20,197, 1 February 2006 through 31 January 2007.

D. S. Karpovich, C. H. Schilling, and D. H. Swenson, “Heating buildings with glycerin residues from biodiesel processing,” Michigan Soybean Promotion Committee, $19,223, 1 May 2006 through 30 April 2008.

Patent

Patent application "Hypertabilizing Antisense Oligonucleotides" for OTT 9101 was filed January 29, 1993. This application describes the invention of a method to hyperstabilize sense‑antisense complexes as potential therapeutic tools to attack HIV, cancer, and other genetic‑based diseases. Patent No. 5,786,138 July 28,1998.

Re-issue:  RE38,169 Swenson July 1, 2003  

Invention Reports

  • Dept. of Energy Small Business Innovation Research Program Invention Report: David H. Swenson and Robert L. Metzger, "Boronated Nitroimidazoles for Neutron Capture Therapy of Cancer." March, 1991.
  • LSU‑Office of Technology Transfer: OTT 9106. David H. Swenson and Lynn O. Post, "Development of a test method for fumonisin B1 and related structures." January, 1991.
  • Technology Transfer: OTT 9112. David H. Swenson, "Development of DNA minor‑groove binding agents based on alkylating pyrroles and space‑filling bicyclic ring systems." January, 1991.
  • LSU‑Office of Technology Transfer: OTT 9114. "Boronated compounds for boron neutron capture therapy of cancer (BNCT)." February, 1991. 
 

Honors and Awards 

Alfred P. Sloan Scholarship (Undergraduate Scholarship Support) 1966‑1970.

NSF Undergraduate Summer Traineeship, University of Minnesota, 1968.

Graduated magna cum laude with B.S. degree in Biochemistry.

 National Cancer Institute Research Traineeship, University of Wisconsin, Madison, 1970‑1975, No. T01‑CA‑5002.

 Sigma XI, The Scientific Research Society, 1975 ‑ present.

 Postdoctoral Fellowship, American Cancer Society, for postdoctoral studies from 1975‑1977, declined in favor of NIH fellowship.

 NIH postdoctoral fellowship for studies from 1975‑1977, No. 5F32‑CA05153.

 Carl J. Norden Distinguished Teaching Award, LSU School of Veterinary Medicine, 1993.

 Elected Honorary Member, Phi Zeta Veterinary Honor Society, 1994.

 Gamma Sigma Delta Honor Roll of Veterinary Medicine Faculty, 1994.

 H. H. Dow Endowed Chair in Chemistry, SVSU, 1996 - present.

Terry Ishihara Award for Co-Curricular Involvement, SVSU, 2002.

Tailgater of the Year, First Winner and Trophy Named “Swenson’s Ladle,” 2001, SVSU.

Barnesville Minnesota High School Distinguished Alumnus, 2007.

 Business Establishment:

  • Co‑established S&A Computer Training, Kalamazoo, MI. 1986.
  • Established and operated Karkinos Biochem, Inc., an Arizona Corporation, from self‑generated funds. Corporate Vice President and Treasurer, 1987‑1992. Karkinos Biochem, Inc. was a Research and Development firm specializing in anticancer technologies.
  • Co‑Established Key‑by‑Key, Inc. Computer training facility in Phoenix, AZ. 1989.
  • Established FloraPharm International, Ltd. in October, 1992. This company was set up for the purpose of sourcing and screening limited quantities of natural products worldwide for anticancer and antiviral activities. Corporate President.  
  • Green Resources Redux, Inc. was established in Saginaw Michigan in August, 2008. The focus of this company is to seek novel resources or common overlooked resources in a region to solve regional problems. It is our desire to turn waste into gold.

References

available upon request  


Publications

Book Chapters

 1.        Swenson, D.H., and Kadlubar, F.F. (1981): "Properties of Chemical Mutagens and Chemical Carcinogens in Relation to Their Mechanisms of Action." In: Microbial Testers: Probing Carcinogenesis (I.C. Felkner, Ed.), Marcel Dekker, Inc., New York, NY, pp. 1‑20.

2.         Swenson, D.H. (1981):  "Metabolic Activation and Detoxication of Aflatoxins." In: Reviews in Biochemical Toxicology, Vol. 3 (R.M. Philpott et al., Eds.), Elsevier‑North Holland, pp. 155‑192.  

3.         Swenson, D.H. (1983):  "Significance of Electrophilic Reactivity and Especially DNA Alkylation in Carcinogenesis and Mutagenesis." In: Dev. in the Science and Practice of Toxicology (A.W. Hayes, et al., Eds.) Elsevier‑North Holland, pp. 247‑254.  

4.         Anders, M.W., Buick, S.D., Carlson, R.G., Dent, J.G., Emmerson, J.L., Fuller, G.C., LeBeau, J.E., Loose, L., Nelson, L.W., Nelson, R.A., Pfitzer, E.A., and Swenson, D.H. (1984):  "Workshop on Toxicology: Determinants of Susceptibility and Predictability. Summary of the Workshop." Pharmacol. Rev. 36, 3S‑14S.

5.         Wierenga, W., Bhuyan, B.K., Kelly, R.C., Krueger, W.C., Li, L.H., McGovren, J.P., Swenson, D.H., Warpehoski, M.A. (1985):  "Antitumor Activity and Biochemistry of Novel Analogs of the Antibiotic, CC‑1065." In: Advances in Enzyme Regulation, Vol. 25 (G. Weber, Ed.) Pergammon Press, New York, pp. 141‑155.  

6.         Law, J.M., McMillin, D.J., Swenson, D.H., and Means, J.C. (1996): Quantification of DNA Adducts in Small Fish Exposed to Alkylating Agents. in: G. Ostrander, ed., Environmental Toxicology and Risk Assessment: Biomarkers of Risk Assessment ‑Fifth Volume, ASTM, Philadelphia, PA, pp. 117-137.

7.         Law, J.M., McMillin, D.J., Swenson, D. H., and Means, J.C. (1996): “DNA Adduct Analysis in Small Fish Species using GC/mass spectrometry.”  In: Ostrander, G, ed., Techniques in Aquatic Toxicology, Lewis Publishers, Boca Raton, FL, pp. 185-204.

 

Journal Publications

1.         Kakade, M.L., Swenson, D.H., and Liener, I.E. (1970):  "Note on the Determination of Chymotrypsin and Chymotrypsin Inhibitor Activity using Casein." Anal. Biochem. 33, 255‑258.

2.         Swenson, D.H., Miller, J.A., and Miller, E.C. (1973):  "2,3‑Dihydro‑2,3‑Dihydroxy‑Aflatoxin B1:  An Acid Hydrolysis Product of an RNA‑Aflatoxin B1 Adduct Formed by Hamster and Rat Liver Microsomes In Vitro." Biochem. Biophys. Res. Commun. 53, 1260‑1267.

3.         Swenson, D.H., Miller, E.C., and Miller, J.A. (1974):  "Aflatoxin B1‑2,3‑Oxide:  Evidence for its Formation in Rat Liver In Vivo and by Human Liver Microsomes In Vitro." Biochem. Biophys. Res. Commun. 60, 1036‑1043.

4.         Swenson, D.H., Miller, J.A., and Miller, E.C. (1975):  "The Reactivity and Carcinogenicity of Aflatoxin B1‑2,3‑Dichloride: A Model for the Putative 2,3‑Oxide Metabolite of Aflatoxin B1." Cancer Res. 35, 3811‑3823.

5.         Swenson, D.H., Farmer, P.B., and Lawley, P.D. (1976):  "Identification of the Methyl Phosphotriester of Thymidylyl(3'‑5')Thymidine as a Product from Reaction of DNA with the Carcinogen N‑Methyl‑N‑Nitrosourea." Chem. Biol. Interact. 15, 91‑100.

6.         Swenson, D.H., Lin, J.‑K., Miller, E.C., and Miller, J.A. (1977):  "Aflatoxin B1‑2,3‑Oxide as a Probable Intermediate in the Binding of Aflatoxins B1 and B2 to Rat Liver DNA and rRNA In Vivo." Cancer Res. 37, 172‑181.

7.         Swenson, D.H. and Lawley, P.D. (1978):  "Alkylation of DNA by the Carcinogens Dimethyl Sulphate, Ethyl Methanesulphonate, N‑Ethyl‑N‑Nitrosourea and N‑Methyl‑N‑Nitrosourea. Relative Reactivity of the Phosphodiester Site Thymidylyl(3'‑5')Thymidine." Biochem. J. 171, 575‑587.      

8.         Frei, J.V., Swenson, D.H., Warren, W., and Lawley, P.D. (1978):  "Alkylation of DNA In Vivo in Various Organs of C57BL Mice by the Carcinogens N‑Methyl‑N‑Nitrosourea and Ethyl Methanesulphonate in Relation to Induction of Thymic Lymphoma. Some Applications of High Pressure Liquid Chromatography." Biochem. J. 171, 1031‑1044.                                     

9.         Fahmy, M.J., Fahmy, O.G., and Swenson, D.H. (1978):  "Aflatoxin B1‑2,3‑Dichloride as a Model of the Active Metabolite of Aflatoxin B1 in Mutagenesis and Carcinogenesis." Cancer Res. 38, 2608‑2816.

10.       Swenson, D.H., Frei, J.V., and Lawley, P.D. (1979): "Induction of Thymic Lymphoma in Mice by the Carcinogenic Alkylating Agent, 1‑(2‑Hydroxyethyl)‑1‑Nitrosourea." JNCI 63, 1469‑1473.

11.       Beranek, D.T., Weis, C.C., and Swenson, D.H. (1980):  "A Comprehensive Quantitative Analysis of Methylated and Ethylated DNA using High Pressure Liquid Chromatography." Carcinogenesis 1, 595‑605.

12.       Swenson, D.H., Harbach, P.R., and Trzos, R.J. (1980):  "The Relationship Between Alkylation of Specific DNA Bases and Induction of Sister Chromatid Exchange." Carcinogenesis 1, 931‑936.

13.       Li, L.H., Swenson, D.H., Schpok, S.L.F., Kuentzel, S.L., Dayton, B.D., and Krueger, W.C. (1982): "CC‑1065 (NSC 298223), a Novel Antitumor Agent that Interacts Strongly with Double Stranded DNA." Cancer Res. 42, 999‑1004.

14.       Beland, F.A., Kadlubar, F.F., and Swenson, D.H. (1982):  "Mechanistic Approaches to Biochemical Toxicology." J. Env. Sci. Health A17, 581‑588.

15.       Swenson, D.H., Li, L.H., Hurley, L.H., Rokem, J.S., Petzold, G.L., Dayton, B.D., Wallace, T.L., Lin, A.H., and Krueger, W.C. (1982):  "Mechanism of Interaction of CC‑1065 (NSC 298223) with DNA." Cancer Res. 42, 2821‑2828.

16.       Mahoney, E.M., Ball, C.J., Swenson, D.H., Richmond, D., Maher, V.M., and McCormick, J.J. (1983):  "Cytotoxicity and Mutagenicity of Aflatoxin Dichloride in Normal and Repair Deficient Diploid Human Fibroblasts." Chem. Biol. Interact. 50, 59‑76.

17.       Hurley, L.H., Reynold, V.L., Swenson, D.H., Petzold, G.C., and Scahill, T.A. (1984):  "Reaction of the Antitumor Antibiotic CC‑1065 with DNA: Structure of a DNA Adduct with Remarkable DNA Sequence Specificity." Science 226, 843‑844.

18.       Reynolds, V.L., Molineax, I.J., Kaplan, D.J., Swenson, D.H., and Hurley, L.H. (1985):  "Reaction of the Antitumor Antibiotic CC‑1065 with DNA. Location of the Site of Thermally Induced Strand Breakage and Analysis of DNA Sequence Specificity. Biochemistry 24, 6228‑6237.

19.       Krueger, W.C., Li, L.H., Moscowitz, A., Prairie, M.D., Petzold, G.L., and Swenson, D.H. (1985): "The Binding of CC‑1065 to Poly‑ and Oligonucleotides." Biopolymers 24, 1549‑1572.

20.       Krueger, W.C., DuChamp, D.J., Li, L.H., Moscowitz, A., Petzold, G.L., Prairie, M.D., and Swenson, D.H.(1986):  "The Binding of CC‑1065 to Thymidine and Deoxyadenosine Oligonucleotides and to Poly(dA).Poly(dT)." Chem. Biol. Interact. 59, 55‑72.

21.       Swenson, D.H., Petzold, G.L., and Harbach, P.R. (1986): "The Binding of 1‑(2‑Hydroxyethyl)‑1‑Nitrosourea to DNA In Vitro and to DNA of Thymus and Marrow in C57BL Mice." Cancer Letters 33, 75‑81.         

22.       Swenson, D.H., Petzold, G.L., Williams, M.G., Li, L.H., Prairie, M.D., and Krueger, W.C. (1988): "Evaluation of DNA Binding Characteristics of Some CC‑1065 Analogs." Chem. Biol. Interact 67, 199‑213. 

23.       Aaron, C.S., Mazurek, J., Zimmer, D.M., and Swenson, D.H. (1989): "The Salmonella mutagenicity test: Evaluation of 29 drug candidates." Mutation Res. 223, 171‑182.

24.       Scahill, T.A., Jenson, R.M., Swenson, D.H., Hatzenbuhler, N.T., Petzold, G.L, Wierenga, W. and Brahme, N.T. (1990): "An NMR Study of the Covalent and Non‑Covalent Interactions of CC‑1065 and DNA." Biochemistry 29:2852‑2860.                          

25.       Metzger, R.L., Laster, R.G., Fairchild, R.G. and Swenson, D.H. (1991): "Biological Efficacy of a Boronated Imidocaptate for Neutron Capture." Proceedings of the American Nuclear Society 1991:5.

26.       Swenson, D.H., K. El‑Bayoumy, G.‑H. Shuie, S. S. Hecht, E. Fiala, F.F. Kadlubar and J. P. Freeman (1993). Synthesis of N‑)Purin‑8‑yl)arylamines. Chem. Res. Toxicol. 6: 480‑485.

27.       Dimski, D.S., H.W. Taylor, J. Taboada, J.L. VanSteenhouse, D.H. Swenson and B.D. Marx (1994). Toxic and Vascular Nephropathy Associated with Orotic Acid Administration in Laboratory Cats. Nephron. 68: 275‑276.

28.       Aaron, C. S., R. L. Yu, P. R. Harbach, J. M. Mazurek, D.H. Swenson, D. Kirkland, R. Marshall, and S. McEnaney (1995). Comparative mutagenicity testing of ceftior sodium. Positive results in in vitro cytogenetics. Mutat. Res. 345: 27‑35.

29.       Kim, D.‑Y., Shih, D. S., Cho, D‑Y. and Swenson, D.H. (1995): Helix‑Stabilizing Compounds CC‑1065 and U‑71,184 Bind to RNA‑DNA and DNA‑DNA Duplexes Containing Modified Internucleotide Linkages and Stabilize Duplexes Against Thermal Melting. Antisense Res. and Dev. 5: 49‑57.

30.       Kim, D.‑Y., Swenson, D. H., Cho, D‑Y., Taylor, H. W. and Shih, D.S. (1995): Helix‑Stabilizing Compound, CC‑1065, Enhances Suppression of Translation by an Antisense Oligodeoxynucleotide. Antisense Res. and Dev. 5: 149‑154.                                

31.       Shaddock, J.G., Feuers, R.J., Chou, M.W., Swenson, D.H. and Casciano, D.A. (1995): Genotoxicity of Tacrine in Primary Hepatocytes Isolated From B6C3F1 Mice and Aged Ad Libitum and Calorie Restricted Fischer 344 Rats. Mutation Res. 344: 79‑88.

32.       Swenson, D.H., Laster, B.H. and Metzger, R.L. (1996): Synthesis and Evaluation of a Boronated Nitroimidazole for Neutron Capture Therapy. J. Med. Chem.39: 1540‑1544.

33.       Swenson, D.H., Hart, B., Vogtmann, M, Plaush, A., Eastland, G.W. Jr., Wiese, K, Vivian, T, and Jungquist, K. (1997): Electrolytic Capture and Recycle of Ni and Zn from Plating Waste. Sur/Fin Technical Proceedings Section H. AESF Press, pp 317‑320.

34.       Huang, H., J. Ahmedin, C. David, S. Barker, D. H. Swenson and J. C. Means (1998). Analysis of DNA Adduct, S‑(2‑(N7‑Guanyl)ethyl)glutathione by Liquid Chromatography/Mass Spectrometry and Liquid Chromatography/Tandem Mass Spectrometry. Analytical Biochem. 265:139‑150.

35.       VanSteenhouse, J.L., Prescott, J.S. and Swenson, D.H.  (1999).  Protection from 1-cyano-3,4-epithiobutane Nephrotoxicity by Aminooxyacetic Acid and Effect on Xenobiotic-metabolizing Enzymes in Male Fischer 344 Rats.  J. Appl. Toxicol.  19: 237-249.

36.       VanSteenhouse, J.L., Dimski, D.S., Taylor, H.W., Swenson, D.H., Taboada, J., and Hosgood, G.  (1999).  Effects of oral administration of orotic acid on hepatic morphologic characteristics and serum biochemical variables in cats.  Am. J. Vet. Res.  60: 749-752.

37.       VanSteenhouse, J.L., Dimski, D.S., Swenson, D.H., and Taboada, J. (1999).  Urinary orotic acid-to-creatinine ratios in cats with hepatic lipidosis.  Am. J. Vet. Res.  60: 753-754.

38.       James, S.J., Pogribna, M., Pogribny, I.P., Melnyk, S., Hine, R.J., Gibson, J.B., Ping, Y., Tafoya, D. L., Swenson, D.H., Wilson, V. L., and Gaylor, D.W.  (1999).  Abnormal folate metabolism and mutation in the methylenetetrahydrofolate gene may be maternal risk factors for Down syndrome.  Am. J. Clin. Nutr.  70: 495-501. 

39.       Book Review of Our Stolen Future, by Theo Colburn, et al., in: Preventive Veterinary Medicine 32: 144‑147 (1997). 

 

Abstracts

1.         Swenson, D.H., Miller, J.A., and Miller, E.C. (1974): "Aflatoxin B1‑2,3‑Dichloride: A Toxic and Reactive Derivative of Aflatoxin B1." Proc. Amer. Assoc. Cancer Res. 15, Abstract No. 171.

2.         Lin, J.‑K., Swenson, D.H., Miller, E.C., and Miller, J.A. (1976): "Macromolecular Adducts of Aflatoxins B1 and B2 in Rat Liver In Vivo." Proc. Amer. Assoc. Cancer Res. 17, Abstract No. 152.

3.         Frei, J.V., Lawley, P.D., Swenson, D.H., and Warren, W. (1978): "Relative Carcinogenic Effectiveness of N‑Methyl‑N‑Nitrosourea (MNUA) and N‑Ethyl‑N‑Nitrosourea (ENUA). Quantitative Relation to Alkylation of O6 of Guanine in DNA." Proc. Amer. Assoc. Cancer Res. 19, Abstract 676.

4.         Beranek, D.T. and Swenson, D.H. (1980): "Separation and Quantitation of Alkylated Bases and Phosphotriesters in Carcinogen‑Treated DNA Using High Pressure Liquid Chromatography (HPLC)." Proc. Amer. Assoc. Cancer Res. 21, Abstract No. 355.

5.         Swenson, D.H., Krueger, W.C., Lin, A.H., Schpok, S.L., and Li, L.H. (1981): "CC‑1065, A Novel Antitumor Agent that Interacts Strongly with Double‑Stranded DNA." Proc. Amer. Assoc. Cancer Res. 22, Abstract No. 857.

6.         Swenson, D.H., Krueger, W.C., Petzold, G.L., Wallace, T.L., and Li, L.H. (1982): "On the Mechanism of Interaction of CC‑1065 with DNA." Proc. Amer. Assoc. Cancer Res. 23, Abstract No. 772.

7.         Petzold, G.L., Harbach, P.R., and Swenson, D.H. (1982): "Comparison of the Alkylation of DNA by the Carcinogen 1‑(2‑Hydroxyethyl)‑1‑Nitrosourea (HNU) and 1‑Ethyl‑1‑Nitrosourea (ENU) In Vitro and In Vivo at Carcinogenic Doses." Proc. Env. Mut. Soc. Abstract Bb‑9.

8.         Swenson, D.H., Woodley, B.J., Petzold, G.L., Scahill, T.A., Kaplan, D.J., and Hurley, L.H. (1983): "The Covalent Binding of the Antitumor Antibiotic CC‑1065 to DNA." Proc. Amer. Assoc. Cancer Res. 24, Abstract No. 980.

9.         Li, L.H., Swenson, D.H., Wallace, T.L., Kuentzel, S.L., Petzold, G.L., Wierenga, W., Martin, D.G., McGovren, J.P., and Krueger, W.S. (1982): "Comparative Biological and Biochemical Effects of CC‑1065 and its Related Degradation Products." 13th International Cancer Congress, Seattle WA.

10.       Trzos, R.J. and Swenson, D.H. (1983): "A Comparison of the Transplacental Micronucleus Test with the Rat Micronucleus Test." Proc. Env. Mut. Soc. Abstract Cb‑2.

11.       Trzos, R.J., Brown, P.K., and Swenson, D.H. (1983): "A Comparison of the transplacental Micronucleus Test with the Rat Micronucleus Test." Michigan Regional Society of Toxicology, Ann Arbor, MI.

12.       Petzold, G.L., Scahill, T.A., Woodley, B.J., and Swenson, D.H. (1983): "Interaction of the Antitumor Antibiotic CC‑1065 (NSC 298223) with DNA." Michigan Regional Society of Toxicology, Ann Arbor, MI.

13.       Elliget, K., Kolaja, G., McGovren, J.P., Swenson, D.H., and Petzold, G.L. (1983): "Effect of CC‑1065 on Mouse Liver Mitochondria." Michigan Regional Society of Toxicology, Ann Arbor, MI.

14.       Mahoney, E.M., Ball, J.C., Swenson, D.H., Richmond, D., Maher, V.M., and McCormick, J.J. (1984): "Cytotoxicity and Mutagenicity of Aflatoxin Dichloride (AFB1‑C12) in Normal and Repair Deficient Diploid Human Fibroblasts." Proc. Env. Mut. Soc. 15, Abstract No. Ba‑10.

15.       Hurley, L.H., Needham‑VanDevanter, Reynolds, V., Wierenga, W., Theriault, N., Krueger, W.C., and Swenson, D.H. (1984): "Characterization of an Adduct Between CC‑1065 and a Defined Oligodeoxynucleotide Duplex." Proc. Amer. Assoc. Cancer Res. 25, Abstract No. 1151.

 16.       Petzold, G.L., Krueger, W.C., Swenson, D.H., Prairie, M.D., and Li, L.H. (1985): "Biochemical and Cytotoxic Effects of CC‑1065 Analogs." Proc. Amer. Assoc. Cancer Res. 26, Abstract No. 887.

17.       Scahill, T.A., Jensen, R.M., Swenson, D.H., and Petzold, G.L. (1985): "An NMR Study of the Covalent and Non‑Covalent Interactions of Antibiotic CC‑1065 with DNA and an Octamer‑Duplex." Fourth Conversation of Biomolecular Stereodynamics.

18.       Swenson, D.H., Petzold, G.L., DeKoning, T.F., Prairie, M.D., and Krueger, W.C. (1986): "Characterization and Use of an Enzyme‑Linked Immunosorbent Assay (ELISA) to Quantify CC‑1065‑DNA Adducts." Proc. Amer. Assoc. Cancer Res. 27, Abstract No. 996.

19.       Mitchell, M.A., Swenson, D.H., Wallace, T.L., Williams, M.G., Petzold, G.L., Aristoff, P.A., Johnson, P.D., and Li, L.H. (1987): "Antitumor and Biochemical Effects of Novel Bifunctional Agents Based on the Alkylating Subunit of CC‑1065." Proc. Amer. Assn. Cancer Res. 28, Abstract No. 1068.

20.       Aaron, C.S., Clough, T., Harbach, P.R., Mazurek, J., Mayo, J., Stankowski, L., Swenson, D., Trzos, R., Valencia, R., Wiser, S.K., Zimmer, D. (1987): "Quantitative Comparative Mutagenicity Testing of a Drug Candidate: Coupling of Knowledge of Mechanisms of Toxification Provides a Powerful Risk Assessment Tool." Environ. Mutagen. 9, Suppl. 8, Abstract No. 1.

21.       Petzold, G.L., Swenson, D.H., Aristoff, P.A. and McGovren, J.P. (1988): "Potent in vitro Inhibition of Poly(ADP)‑Ribosylation in Chinese Hamster Ovary (CHO) Cells by Flavone and Related Analogs, Including Flavone Acetic Acid." Proc. Amer. Assn. Cancer Res. 29: Abstract No. 64.

22.       Casciano, D.A, Shaddock, J.G., Feuers, R.J. and Swenson, D.H. (1990): "An Evaluation of the Genotoxicity of Tetrahydroaminoacridine (THA) in the in vitro Rodent Hepatocyte Unscheduled DNA Synthesis (UDS) Assay.: Env. Mol. Mutagenesis 15: p12.

23.       Casciano, D.A, Shaddock, J.G., Feuers, R.J. and Swenson, D.H. (1991): "Effects of Aging and Caloric Restriction on the Genotoxicity of Tetrahydroaminoacridine (THA) in the in vitro Rat Hepatocyte/DNA Repair Assay." Proc. Amer. Assn. Cancer Res. 32: Abstract No. 672.

24.       Swenson, D.H., Freeman, J.P., and Kadlubar, F.F. (1991): "Synthesis of Purin‑8‑yl Arylamine Adducts via Isothiocyanates." Proc. Amer. Assoc. Cancer Res. 32: Abstract No. 530.

25.       Annan, M., Giese, R.W., Vouros, P., and Swenson, D.H. (1992): "Structural Characterization of Alkylated DNA Using Electrospray Ionization Mass Spectrometry." Proceedings of the ASMS Conference on Mass Spectrometry and Allied Topics 40: 1637‑1638.

26.       Swenson, D.H., Laster, B.H., Gordon, C.R. and Metzger, R.L. (1993): Evaluation of a Boronated 5‑Nitroimidazole for Neutron Capture Therapy. Proc. Amer. Assn. Cancer Res. 34: 361.

27.       Kim, D.‑Y. and Swenson, D.H. (1993): Binding and Stabilization of DNA Duplexes with CC‑1065 and U‑71,184. Proc. Amer. Assn. Cancer Res. 34: 352.

28.       Fossett, N.G., Swenson, D.H., Chang, S.H., Lin, Z., Tucker, A., and Lee, W.R. (1993): 2‑Chloroethyl Methanesulfonate as a Model for Bifunctional Alkyl Halides. Environ. Mol. Mutagen. 21 (Suppl. 22): 20.

29.       Shane, B.S., Winston, G. ., Arbour‑Reilly, P. , Schaeffer, D.O., Battista, J. ., Swenson, D.H., Chang, S.H., and Lee, W.R. (1993): Mutation Frequency of Benzo(a)pyrene in Rapidly Dividing Cells of the Liver of C57BL/6 Transgenic Mice. Environ. Mol. Mutagen. 21 (Suppl. 22): 64.

30.       Kim, D.‑Y., Shih, D.S., Cho, D.Y. and Swenson, D.H. (1994): Hyperstabilization of Sense‑Antisense Duplexes and Inhibition of Translation. Proc. Amer. Assn. Cancer Res. 35: 308.

31.       Law, J.M., Means, J.C., McMillin, D.J., Swenson, D.H., Taylor, H.W., Hawkins, W.E. and Walker, W. W. (1994). 15th SETAC Meeting, November 1‑3, Denver Co. 

32.       Law, J. M., Taylor, H.W., Means, J.C., McMillin, D.J., Swenson, D.H., et al. Annual Phi Zeta Research Meeting, March 22, 1994, Baton Rouge. 

 

Invited Symposium Presentations

1.         "Modification of Specific Sites in DNA by Carcinogenic Alkylating Agents." Third Southwest Regional Meeting, American Chemical Society, Little Rock, AR (1977).

2.         "Reactivity and Selectivity of Carcinogenic Alkylating Agents." Second Chemical Congress of the North American Continent/American Chemical Society National Meeting, Las Vegas, NV (1980).

3.         "Significance of Electrophilic Reactivity and Especially DNA Alkylation in Carcinogenesis and Mutagenesis." Third International Congress on Toxicology, San Diego, CA (1983).

4.         "The Covalent Binding of the Antitumor Antibiotic CC‑1065 to DNA." American Association for Cancer Research Minisymposium. San Diego, CA (1983).

5.         "How Chemicals Can Damage DNA to Cause Cancer." Joint Great Lakes and Central Regional American Chemical Society Meeting, Kalamazoo, MI (1984).

6.         "Mutagenicity and In Vitro Carcinogenicity Testing." American Society for Clinical Pathology National Meeting, New Orleans, LA (1984).

7.         "Modification of Specific Sites in DNA: Mechanisms in Carcinogenesis and Targeted Toxicity." Michigan Chapter of the Soc. of Toxicology/Great Lakes Group of the Society of Toxicologic Pathologists ‑ Joint Annual Meeting, Ann Arbor, MI (1985).

8.         "Hyperstabilization of Sense‑Antisense Duplexes and Inhibition of Translation." Presented by Dr. Kim at the American Association for Cancer Research Annual Meeting in San Francisco, CA (1994).

 

Technical Reports  

120 confidential technical reports on the genetic toxicology of proprietary pharmaceutical candidates, including mechanism of genotoxicity were prepared for The Upjohn Co. from 1979‑1987. Titles and report contents are confidential.  

Technical report was issued to Schering‑Plough on a potential toxicology problem, as part of consultation while operating Karkinos Biochem, Inc., in 1988. Contents and title of technical report are confidential.  

Technical report was issued to National Cancer Institute: D.H. Swenson, "Synthesis of Monomeric Carcinogen‑DNA Adducts." (1990). Karkinos Biochem, Inc. Report Number 90‑1. This Technical Report was the final report for a Small Business Innovation Research Grant to Karkinos Biochem, Inc.  

Technical report issued to Dept. of Energy: D.H. Swenson and R. L. Metzger, "Boronated Nitroimidazoles for Neutron Capture Therapy of Cancer." (1991). Karkinos Biochem, Inc., Report No. 91‑1. This Technical Report was the final report for a Small Business Innovation Research Grant to Karkinos Biochem, Inc.  

Technical Report, The Upjohn Co. Content confidential, January 1998.

 

Invited Seminars and Lectures

"DNA Alkylation by Oncogenic Alkylating Agents." for the Toxicology Program's chemical carcinogenesis course at Michigan State University, 1982. (Veronica Maher, Ph.D. and J. Justin McCormick, Ph.D., course coordinators).

"Binding of Electrophilic Carcinogens to Cellular Macromolecules," and "Interaction of Organic Chemical Carcinogens with DNA." for the Interdisciplinary Toxicology Program's carcinogenesis course at the University of Arkansas for Medical Sciences, Little Rock, 1978. (Joan Spyker‑Kranmer, Ph.D., course coordinator).

"Metabolic Activation and Binding of Genotoxic Carcinogens to DNA." for the Dept. of Biomedical Sciences' course on biology of cancer at Western Michigan University, Kalamazoo, MI, 1986. (Leonard Beuving, Ph.D., course coordinator).

Mutagenesis (ZOOL 7153) ‑ lectures on interactions of chemical mutagens with DNA and their effects. These lectures entailed three contact hours in this three‑credit course, LSU, 1992. (W. R. Lee, course coordinator).

Individual lectures at LSU in ENVS 4500 on DNA adduct formation, and in ENVS 7100, 4 lecture hr each, (V. Wilson, course coordinator), 1994‑1996.

Individual lectures at LSU in ENVS 7626 (Genetic Toxicology) on DNA adduct formation, genetic database access on the internet, and consequences of DNA alkylation 7.5 lecture hr, (V. Wilson, course coordinator), 1996.

"DNA Adducts as Tools for Molecular Epidemiology in Cancer." LSU Dept. ECH, ECH 7003, 1995 (M. Groves, course coordinator).

"DNA Adducts as Tools for Molecular Epidemiology in Cancer." LSU Dept. ECH, ECH 7003, 1996 (M. Hugh‑Jones, course coordinator).

"Electrophilic and Ultimate Carcinogenic Derivatives of Alfatoxin B1." Institute of Cancer Research, Pollards Wood Research Station, Chalfont St. Giles, Bucks, ENGLAND (October 1975).

"Recent Results in Aflatoxin Research." International Agency for Research on Cancer, Lyon, FRANCE (February 1976).

"Alkyl Phosphotriesters of Thymidylyl (3'‑5') Thymidine: Evidence for Their Formation by Alkylating Agents In Vitro." McArdle Laboratory for Cancer Research, University of Wisconsin, Madison, WI (November 1976).

"Aflatoxin B1‑2,3‑Oxide: A Probable Ultimate Carcinogenic Metabolite of Aflatoxins B1 and B2." M.D. Anderson Hospital, Biol. Division, Houston, TX (November 1976).

"Aflatoxin B1‑2,3‑Oxide: A Probable Ultimate Carcinogenic Metabolite of Aflatoxins B1 and B2." Cancer Research Center, University of North Carolina, Chapel Hill, NC (November 1976).

"Aflatoxin B1‑2,3‑Oxide: A Probable Ultimate Carcinogenic Metabolite of Aflatoxins B1 and B2." National Center for Toxicological Research, Jefferson, AR (November 1976).

"Alkyl Phosphotriesters of Thymidylyl (3'‑5') Thymidine: Evidence for Their Formation by Alkylating Agents In Vitro." National Center for Toxicological Research, Jefferson, AR (November 1976).

"Aflatoxin B1‑2,3‑Oxide as a Probable Intermediate in the Covalent Binding of Aflatoxins B1 and B2 to Rat Liver DNA and rRNA In Vivo." Department of Cancer Research, Chemistry Division, York University, York, ENGLAND (February 1977).

"Aflatoxin B1‑2,3‑Oxide as a Probable Ultimate Carcinogenic Metabolite of Aflatoxins B1 and B2." MRC Toxicology Unit, Carshalton, Surrey, ENGLAND (February 1977).

"The Metabolism of Aflatoxin B1 and Vinyl Chloride to Ultimate Carcinogens." Cortauld Institute of Biochemistry, London, ENGLAND (May 1977).

 "Alkylation of DNA and Carcinogenesis." Biochemistry Department, University of Arkansas for Medical Sciences, Little Rock, AR (May 1978).

"Alkylation of DNA in Relation to Induction of Thymic Lymphoma." Department of Medicinal Chemistry, Purdue University, West Lafayette, IN (July 1978).

"Alkylation of DNA and Induction of Thymic Lymphoma in Mice." The Upjohn Company, Kalamazoo, MI (November 1978).

"Alkylation of DNA in Relation to Induction of Thymic Lymphoma in Mice." Department of Biology, Western Michigan University, Kalamazoo, MI (September 1979).

"Alkylation of DNA in Relation to Carcinogenesis." Chemical Carcinogenesis Division, Michigan Cancer Foundation, Detroit, MI (March 1980).

"Analysis of DNA Adducts by HPLC." Canadian Mutagenesis Gathering, University of Western Ontario, London, Ontario, CANADA (May 1980).

"CC‑1065: A Novel Antitumor Agent that Interacts with Double‑Stranded DNA." National Center for Toxicological Research, Jefferson, AR (April 1981).

"The Interaction of CC‑1065 with DNA." Department of Pharmacy, University of Texas, Austin, TX (May 1982).

"CC‑1065: An Antitumor Agent that Binds Double‑Stranded DNA." McArdle Laboratory for Cancer Research, University of Wisconsin, Madison, WI (December 1982).

"Further Studies on Binding of the Antitumor Agent, CC‑1065, to DNA." McArdle Laboratory for Cancer Research, University of Wisconsin, Madison, WI (November 1983).

"CC‑1065: A Novel Antitumor Antibiotic that Reacts with DNA." Medical College of Ohio, Toledo, OH (February 1984).

"CC‑1065: A Novel Antitumor Antibiotic that Reacts with DNA." Department of Pharmacy, Purdue University, West Lafayette, IN (February 1984).

"The Interaction of CC‑1065, A Novel Antitumor Antibiotic, with DNA." Department of Pharmacology, Uniformed Services University of the Health Sciences, Bethesda, MD (October 1984).

"How Chemicals Can Damage DNA to Initiate Cancer." Department of Chemistry, Central Michigan University, Mt. Pleasant, MI (April 1985).

"The Mechanism of Action of a Novel Class of DNA‑Reactive Antitumor Agent." Department of Pharmacology, Michigan State University, East Lansing, MI (October 1985).

"The Interaction of CC‑1065, a Representative of a Novel Class of Antitumor Agent, with DNA." Department of Biochemistry, Texas College of Osteopathic Medicine, Fort Worth, TX (May 1986).

"The Interaction of the Antitumor Antibiotic, CC‑1065, and Its Synthetic Analogs with DNA." Michigan Cancer Foundation, Detroit, MI (October 1986).

"The Interaction of the Antitumor Antibiotic, CC‑1065, and Related Analogs With Nucleic Acids." Department of Pharmacology, University of Arizona Cancer Center, Tucson, AZ (October 1987).

"Studies With an Anticancer Agent Based on a Natural Product." Dept. Veterinary Physiology, Pharmacology and Toxicology, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA (September 1990).

"Development of an Anticancer Agent Based on a Natural Product." Institute for Mutagenesis, Louisiana State University, Baton Rouge, LA (February 1991).

"Mechanism of CC‑1065, an Anticancer Agent That Binds in the Minor Groove of DNA." Dept. of Epidemiology and Community Health, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA (February 1991).
 

"Development of an Antitumor Agent Based on a Natural Product and its Application to Antisense Hyperstabilization." Dept. of Vet. Microbiology and Parasitology, Louisiana State University, Baton Rouge, LA (October 1991).

"Recent Results with DNA Helix Stabilizing Drugs." Student Chapter of the AAHA, Baton Rouge, December, 1991.

"Hyperstabilizing Antisense Oligonucleotides: A New Therapeutic Concept." Dept. of Vet. Physiol. Pharmacol. & Toxicol., Louisiana State University, April, 1993.

"Hyperstabilizing Antisense Oligonucleotides: A New Therapeutic Concept." National Center for Toxicological Research, Jefferson, AR April 13, 1993. 

"Development and Testing of a Boronated Nitroimidazole for Neutron Capture Therapy." Dept. of Biochemistry, Louisiana State University, September, 1993.

"Development and Testing of a Boronated Nitroimidazole for Neutron Capture Therapy." Vet. Physiol. Pharmacol. & Toxicol., Louisiana State University, September, 1993.

"Design, Synthesis and Testing of a Boronated Nitroimidazole for Neutron Capture Therapy." LSU Dept. Chemistry, October, 1994.

Hyperstabilizing Antisense Oligonucleotides: A New Therapeutic Concept.  Saginaw Valley State University, February, 1996.

Biochemistry of Gene Overexpression in Down Syndrome. Trisomy 21 Research Group, Windsor College, Canada, October, 1996.

Subsequent presentations of Biochemistry of Gene Overexpression in Down Syndrome were presented in 1996 and 1997 to:

SVSU Board of Fellows, University Center, MI, Fall 1996.

Trisomy 21 Research Group, St. Mary’s College, South Bend, IN, October, 1996.

Down Syndrome Group of the ARC, Midland, MI Fall 1996.

Midland (MI) Rotary Club, Fall 1996.

Rotary Club (evening group) Northwood University, Midland, MI, Fall 1997.

FRIENDS of TRI Parent/Physician Group, Cherry Hill, NJ, Spring 1997.

FRIENDS of TRI Parent/Physician Group, Penn State University, Spring 1997.

FRIENDS of TRI Parent/Physician Group, Syracuse Univ., Summer 1997.

FRIENDS of TRI Parent/Physician Group, Ogden, UT, Fall 1997.

TRI Science Advisory Board, Virginia Beach, VA, Fall 1997.

British Down Syndrome Assn. (2 presentations), London, UK, Fall 1997.

FRIENDS of TRI Parent/Physician Group, South Bend, IN, Fall 1997.

Update on Research in Alzheimer’s Disease and Down Syndrome.  Midland Rotary Club., Midland, MI December, 1999. 

Technology Transfer

  • LSU‑Office of Technology Transfer: OTT 9101. David H. Swenson "Use of normally charged or uncharged oligonucleotides with specific coding sequences to specifically deliver a double‑strand nucleic acid‑binding agent." January 1991.